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Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an
aggressive neoplasm derived from plasmacytoid dendritic
cells.1 In 2008, BPDCN was classified by the World Health
Organization (WHO) as a distinct entity in the group of
“acute myeloid leukemia (AML) and related precursor neo-
plasms”.2 Although elderly subjects are principally affected,
BPDCN can also arise in young adults and children.3,4
Approximately 90% of patients exhibit cutaneous lesions at
diagnosis, which upon microscopic analysis appear as a der-
mal infiltrate of immature blastic cells with features of plas-
macytoid dendritic cells.5,6 Malignant cells isolated from skin,
lymph nodes, bone marrow, spleen and/or other tissues usu-
ally express the following markers: interleukin-3 receptor
alpha (IL-3Ra or CD123), BDCA2 (CD303), BDCA4 (CD304),
TCL1 and ILT7.7-9
Currently, there is no consensus regarding the optimal
treatment modality for BPDCN. Several treatments, including
multi-agent chemotherapy regimens, symptomatic approach-
es (e.g. local radiation10), and intensive chemotherapy with
allogeneic hematopoietic cell transplantation,11-13 are generally
used to treat patients. Although chemotherapy regimens used
to treat patients with acute leukemia or lymphoma are often
effective at inducing an initial response, the duration of
response is typically brief and recurrent disease is generally
resistant to chemotherapy. BPDCN patients generally suc-
cumb to cytopenias due to tumor infiltration of the bone mar-
row; the median overall survival has been reported to range
from 9 to 32 months irrespectively of the initial presentation
of the disease.14-16 While longer overall survival has been
reported with allogeneic hematopoietic cell transplantation,
especially in younger patients,4,11,13,16,17 many relapses have
been observed after such transplants.13
The a-subunit of the human IL-3 receptor is a type I trans-
membrane glycoprotein belonging to the cytokine receptor
superfamily.18,19 Interleukin-3 (IL-3) the IL-3 receptor is a he -
terodimer associating an a chain (CD123) and a β chain
(CD131). This chain is shared by IL-3, IL-5, and granulocyte-
macrophage colony-stimulating factor receptors. SL-401, a
novel biologic targeted therapy directed against the IL-3R, is
comprised of human recombinant IL-3 joined by an acid-
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Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells.
There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never
been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of inter-
leukin-3 receptor a chain (IL3-Ra or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401
against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401
was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in
primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an
in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic
agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-
dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentra-
tions than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic
cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated con-
trols (median survival, 58 versus 17 days, P<0.001). These findings indicate that blastic plasmacytoid dendritic cell
neoplasm cells are highly sensitive to SL-401, and support further evaluation of SL-401 in patients suffering from
blastic plasmacytoid dendritic cell neoplasm.
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ABSTRACT
labile group of amino acids to a diphtheria toxin (DT) pay-
load that has been truncated at its receptor binding
region.20 Since IL-3, the natural ligand for IL-3R, binds with
very high specificity and avidity,21 SL-401 is able to trans-
port DT efficiently and preferentially to cells that over-
express IL-3R, leading to internalization followed by
receptor-mediated endocytosis and localization of SL-401
to early endosomes. After cleavage of the SL-401 DT con-
stituent in the acidic medium of endosomes, DT translo-
cates into the cytosol and binds to ADP-ribosylated elon-
gation factor 2, leading to blockade of protein synthesis
and cell death.22
Given the ubiquitous and high expression of IL-3R by
BPDCN and the lack of therapies available to treat
BPDCN, SL-401 is a potential therapeutic for BPDCN. The
present study evaluated the cytotoxicity of SL-401 against
patient-derived BPDCN cell lines (CAL-1 and GEN2.2) and
primary BPDCN cells isolated directly from 12 patients.
The investigations were performed in vitro, as well as in
vivo in a murine model of BPDCN. The aim of the study
was to provide further support for the use of SL-401 in
patients suffering from BPDCN. 
Methods
Patients’ cells and cell lines 
Peripheral blood or bone marrow cells were obtained for diag-
nostic purposes from 12 BPDCN patients (Table 1) from our
national network that collects data and cells from cases diagnosed
in France since 2004 (authorization number #DC-2008-713).
BPDCN was diagnosed from the results of histopathology and
immunostaining of cutaneous lesions, blood or bone marrow.2,8
Two established cell lines derived from BPDCN patients were
used (GEN 2.2, patent #0215927, Dr. Plumas, EFS Rhone-Alpes,
Grenoble, France and CAL-1, Dr. Maeda, Nagasaki University,
Japan) as well as TF/H-Ras (Prof. Frankel) and CD123neg (MFI<800)
Daudi cell lines (ACC78, DSMZ Braunschweig, Germany) as pos-
itive and negative controls, respectively. Other lymphoid and
myeloid leukemic cells used to compare sensitivity to SL-401 are
described in the Online Supplementary Appendix. 
Drug and culture
The SL-401 drug (Stemline Therapeutics, New York, NY, USA)
was stored at -80°C and tested at eight concentrations ranging
from 365 pM to 0.08 fM (21 ng/mL to 0.4 ng/mL) in order to cover
Table 1. Characteristics of the 12 patients suffering from blastic plasmacytoid dendritic cell neoplasm (BPDCN) who provided primary BPDCN cells.
Patient Age/ Immunophenotype Karyotype Cutaneous Pathology Sites of disease
number gender (flow cytometry) lesions diagnosis involvement
#1 75/M CD4+ CD56+ CD123++ CD303+ CD304+ 45,XY,-5 [3], 46XY [10] no NA LN, BM blood,
My- B- CD7+ (others T-) spleen
#2 59/M CD4+ CD56+ CD123++ CD303- CD304+ 46,XY,del(6q)(q16q25),der(7)t(7;12) yes BPDCN LN, BM skin
CD33+ (others My-) B- CD7+ (others T-) (p11;q1?3),?del(7)(p21),-8x2,-9x2,-12x2,
+mar [4], 46XY [11]
#3 81/M CD4+ CD56+ CD123++ CD303+ CD304+ 46XY yes BPDCN LN, BM, skin, blood
CD33+ (others My-) CD22+ (others B-)CD2+
(others T-)
#4 69/M CD4+ CD56+ CD123++ CD303+ CD304+ 46XY yes BPDCN skin, BM
CD33+ (others My-)CD22+ (others  B-) CD7+
(others T-)
#5 63/M CD4+ CD56+ CD123++ CD303+ CD304+ 44,X,-Y,-13[3]/44,sl,i(7)(q10)[15]/45,XY,-15[3] yes BPDCN LN, BM skin blood,
TCL1+ My- B- T- spleen
#6 56/M CD4+ CD56+ CD123++ CD303- CD304+ NA yes NA BM, skin, blood
TCL1+ ILT7- CD33+ CD117+ (others My-) 
CD22+ (others B-) CD7+ (others T-)
#7 33/M CD4+ CD56+ CD123++ CD303- CD304+ 44,X,Y,13[3]/44,sl,i(7)(q10)[15]/45,XY,-15[3] yes BPDCN BM, skin, blood
TCL1+ ILT7- My- B- T-
#8 70/F CD4+ CD56+ CD123++ CD303+ CD304+ 46,XX i(7q) yes BPDCN LN, BM, skin, 
TCL1+ ILT7- My- B- T- blood, spleen
#9 72/M CD4+ CD56+ CD123++ CD303- CD304+ NA yes NA LN, BM, skin, blood
TCL1+ ILT7- My- B- CD2+ CD7+ (others T-)
#10 63/M CD4+ CD56+ CD123++ CD303+ CD304+ 46XY yes BPDCN BM, skin, blood
TCL1+ ILT7- My- B- CD2+ CD7+ (others T-)
#11 58/M CD4+ CD56+ CD123++ CD303+ 46XY yes BPDCN LN, BM, skin,
CD304+TCL1+ ILT7+ CD33+ (others My-) B- T- spleen
#12 80/M CD4+ CD56+ CD123++ CD303- CD304+ TCL1+ 43-44,XY,der(2) t(2;?)(q23;?),der(4)t(4;?) yes BPDCN LN, BM, skin, blood,
ILT7- My- B- CD7+ (others T-) (q35;?),5,der(7)t(7;?)(q31;?),-9,-10,-13,-15, spleen
-16,del(17)(p11),+1-4mar[17];82 83,idemx2
[12];46,XY
Age (years)/gender; Results of phenotypic analysis performed on blood or bone marrow samples (flow cytometry); karyotype; presence of cutaneous lesions; histopathological diagnosis. My: myeloid
markers (including myeloperoxidase, CD13, CD33, CD117, CD15, CD65, CD14, CD64); T : T lymphoid markers (including membrane CD3, intracytoplasmic CD3, CD7, CD5, CD2, CD8); B: B lymphoid
markers (including intracytoplasmic CD79a, intracytoplasmic CD22, intracytoplasmic Ig m chains, CD19, CD20, CD22, surface immunoglobulin); +: positive expression; ++: high expression; -: absence
of expression; NA: not available; LN: lymph nodes; BM: bone marrow.
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the concentrations obtained in vivo in patients enrolled in clinical
trials.23,24 The effects of chemotherapy agents used in acute
leukemia were also evaluated against BPDCN cells (Online
Supplementary Appendix). BPDCN cells were incubated at 3x105
cells/mL in RPMI 1640 glutamax medium (Invitrogen, Cergy
Pontoise, France) supplemented with 10% fetal calf serum
(Invitrogen), 1% penicillin/streptomycin (PAA Laboratoires,
Velizy Villacoublay, France) with or without SL-401 or the relevant
drugs under 5% CO2 for 18 h at 37°C. 
Cytotoxicity evaluation by flow cytometry
Flow cytometry was performed using a CANTO II cytometer
(BD Biosciences, San Jose, CA, USA) and DIVA 6.2 software (BD
Biosciences). The cytotoxic effects of SL-401 and the various drugs
were evaluated using annexin-V and 7-amino actinomycin D
(AV/7AAD) and a panel of different monoclonal antibodies to gate
the blastic population described in the Online Supplementary
Appendix. In the mouse model, anti-mouse and anti-human CD45
plus anti-human CD123, CD4, CD56, CD304 were used to iden-
tify BPDCN human cells (Online Supplementary Appendix). A
defined number of calibrated 3-mm latex beads (Flowcount beads,
Beckman Coulter) was added to each sample to obtain the
absolute number of circulating BPDCN cells in mice, as previously
described.25
Cytotoxicity evaluation by the MTT assay
The percentage of viable cells obtained after incubation with or
without SL-401 was assessed using the MTT assay (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma
Aldrich, Saint Quentin Fallavier, France). Details of the culture and
following analysis are provided in the Online Supplementary
Appendix.
Mice
NOD-SCID IL2Rγc-deficient (NSG) mice were irradiated (2 Gy)
and inoculated intravenously 24 h later with 1x106 GEN2.2 cells
and treated intraperitoneally 8 days later with five daily injections
of SL-401 (2 mg/mouse/injection, total experimental dose 100
mg/kg) or with phosphate-buffered saline (PBS) only. Mice were
monitored weekly by blood cell counts and flow cytometry
(Online Supplementary Appendix).
Statistical analysis
Statistical analyses were performed using Statel software 2.6
(Adscience, Paris, France) (Online Supplementary Appendix). 
Results
SL-401 is cytotoxic against blastic plasmacytoid den-
dritic cell neoplasm cell lines and primary cells
The viability of the two CD123pos BPDCN cell lines,
GEN2.2 and CAL-1, decreased from 62 ± 6% (range, 44-
96) to 5 ± 2% (range, 0-17) after treatment with SL-401 at
the experimental dose of 365 pM (21 ng/mL) for 18 h (n=9,
Figure 1A). Moreover the viability of these two BPDCN
cell lines decreased in a dose-dependent manner (Figure
1B). Similarly, after treatment with SL-401 at the experi-
mental dose of 365 pM (21 ng/mL), the viability of 12 sam-
ples of freshly isolated BPDCN primary cells decreased
significantly from 50 ± 4% (range, 31-71) to 10 ± 1%
(range, 3-17). As expected, the CD123neg (Daudi) cells were
not sensitive to treatment with SL-401 concentrations as
high as 365 pM for 18 h [viability was unchanged from
65% (range, 88-41) to 61% (range, 83-41) in cells untreated
or treated with SL-401, respectively, n=3; Figure 1A,B].
SL-401 is cytotoxic against blastic plasmacytoid 
dendritic cell neoplasm primary cells in a
concentration-dependent manner
The viability of primary malignant cells obtained from
12 BPDCN patients treated with SL-401 for 18 or 48 h
decreased in a concentration-dependent manner, as
assessed by flow cytometry and MTT (Figure 1C,D). As
expected, CD123neg Daudi cells were resistant to SL-401
treatment (Figure 1C,D). For patient #10, primary BPDCN
cells were obtained at both the time of diagnosis and di -
sease relapse following treatment with chemotherapy
[including CHOP (cyclophosphamide, hydroxydaunoru-
bicin, vincristine, and prednisone), methotrexate, and L-
asparaginase]. Interestingly, BPDCN cells obtained at di -
sease recurrence were slightly more sensitive to SL-401
than cells obtained at diagnosis (IC50, 6 fM versus 79 fM,
respectively; P=0.049; Figure 1E). Thus, relapsing cells
were still sensitive to SL-401 in a concentration-dependent
manner, indicating that BPDCN cells retain their sensitivi-
ty to SL-401 following treatment with various cytotoxic
agents, thereby suggesting a lack of cross-resistance. 
SL-401 is more efficient than other tested 
chemotherapeutic drugs − except idarubicin − 
at killing blastic plasmacytoid dendritic cell
neoplasm cells 
In order to appreciate the cytotoxic effect of SL-401
better, we also assessed the effects of other chemothera-
peutic drugs. Primary malignant cells obtained from
three BPDCN patients (#7, #9 and #11) were significantly
more sensitive to SL-401 than to a wide variety of cyto-
toxic agents commonly used for the treatment of hema-
tologic malignancies, including cytosine arabinoside,
cyclophosphamide, vincristine, dexamethasone,
methotrexate, Erwinia L-asparaginase, and asparaginase
(Figure 2; P<0.05 for all agents). Only idarubicin was
found to be more efficient than SL-401 (viability <1%,
n=5; Figure 2).
Blastic plasmacytoid dendritic cell neoplasm primary
cells are more sensitive to SL-401 than acute myeloid
or lymphoblastic leukemia primary cells in vitro
We next assessed the viability after SL-401 treatment of
primary malignant cells isolated from three previously
untreated patients suffering from acute lymphoblastic
leukemia and six untreated patients suffering from AML.
We compared these results to those achieved following
SL-401 treatment of primary BPDCN cells. The viability of
the leukemic cells decreased slightly after treatment with
SL-401 (365 pM for 18 h). We observed an average
decrease of 13% in viability for acute lymphoblastic
leukemia cells [33±20% (range, 6-73) to 26±20% (range, 4-
69), n=3] and 16% for AML cells [40±8% (range, 18-75) to
36±8% (range, 11-70), n=6]. BPDCN cells were signifi-
cantly more sensitive to SL-401 and had a  75% decrease
in viable cells [50±5% (range, 20-71) to 11±1%, (range, 4-
17) n=11; P<0.001; Figure 3]. 
CD123 expression correlates with SL-401 
cytotoxicity in vitro
We next compared the relative expression levels of IL-
3Ra (CD123) and β (CD131) chains in primary malignant
IL-3R-targeted treatment of BPDCN
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BPDCN cells, acute leukemic cells, as well as established
BPDCN cell lines to the respective sensitivities to SL-401
(Table 2). Overall, sensitivity of primary BPDCN cells
was related to CD123 expression, as demonstrated by
the inverse relationship between cell viability and
CD123 expression (Spearman test: r = -0.58, P<0.012).
The high dependence of plasmacytoid dendritic cell line-
age cells (including normal or leukemic plasmacytoid
dendritic cells) to IL-3 may also contribute to the high
sensitivity of BPDCN cells to deprivation of IL-3 signal-
ing during SL-401 exposure. Importantly, no such rela-
tionship was observed for CD131 (Spearman test: r =
F. Angelot-Delettre et al.
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Figure 1. Sensitivity of BPDCN cells to SL-401-mediated death. (A) A representative experiment is shown. Upper panels: dot plots showing the
staining of annexin V (AV FITC) and 7-AAD, on the x- and y-axes, respectively, as assessed by flow cytometry (FC), on IL-3R non-expressing Daudi
cells (negative control) and CAL-1 cells (established BPDCN patient-derived cell line) after treatment with SL-401 (365 pM) for 18 h; lower pan-
els: primary blasts from BPDCN patient #1 after treatment with SL-401 (365 pM, right hand side panel) for 18 h or no drug treatment (no SL-
401, left hand side panel). The percentages indicated in each dot plot represent viable cells (AV-/7-AAD- cells). (B) The percent viability (mean
± SEM) of the BPDCN cell lines CAL-1 (n=3) and GEN 2.2 (n=6) after treatment with SL-401 at different concentrations ranging from 0.08 fM
to 365 pM (0-21 ng/mL) for 18 h. The Daudi cell line was used as a negative control. (C) Each gray line represents the percentage viability of
primary blasts (AV-/7-AAD- cells) isolated from different BPDCN patients (#1-12) according to different SL-401 concentrations (from 0.08 fM
to 365 pM = 0-21 ng/mL) for 18 h. The black line represents the mean of BPDCN patients’ samples as a function of SL-401 concentration;
the Daudi cell line was used as a negative control. (D) Viability assessed using the MTT assay: the percentage viability of primary blasts from
BPDCN patients #3 and #4 and of CAL-1 and GEN 2.2 BPDCN cell lines is dependent on SL-401 concentrations. The Daudi cell line was used
as a negative control and is insensitive to SL-401-mediated death whatever the concentration of the drug used. Cells were treated with SL-
401 for 48 h. The values represent the results of one experiment for patients’ samples or three independent experiments for cell lines. (E)
Percentage (mean ± SEM) of viable primary BPDCN cells (AV-/7-AAD- cells) from patient #10 at diagnosis (n = 3) and at relapse (n=6) after
incubation for 18 h with different concentrations of SL-401 or without any drug, as assessed using annexin V and 7-AAD staining and flow
cytometry (FC). Untreated cells were considered as 100% viable (P=0.049).
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0.01, P<0.93). For patient #10, the MFI of CD123 was
quite similar both at diagnosis and relapse (5509 versus
5137, respectively).
Treatment with SL-401 significantly increases the over-
all survival of NSG mice inoculated with blastic plas-
macytoid dendritic cell neoplasm cells
Irradiated NGS mice were inoculated with the GEN2.2
cell line (1x106 cells per mouse) through the tail vein. Eight
days after inoculation, mice were treated with a daily
intra-peritoneal injection of SL-401 (2 mg/day) for 5 days or
with PBS as controls (n=8 mice in 3 independent experi-
ments). In PBS-treated control mice, the mean overall sur-
vival was 17±1 days. Treatment with five daily injections of
SL-401 significantly increased the overall survival of mice
compared to that of control mice (58 ± 2 days; P<0.001;
Figure 4A,B). Circulating BPDCN cells were identified as
human CD45pos, CD123pos, BDCA4pos, CD4pos, CD56pos,
CD3neg, and CD34neg cells (Figures 4C). Nearly all of the
BPDCN cells expressed CD123 when mice developed the
BPDCN (Figure 4C). This suggests that one course of SL-
401 (2 µg/day for 5 days) is not sufficient to kill all of the
BPDCN cells, rather that CD123neg BDPCN cells emerge in
response to SL-401. In PBS-treated control mice, the num-
ber of BPDCN cells progressively increased until death,
whereas treatment for 5 days with SL-401 successfully
reduced circulating BPDCN cells to undetectable levels for
15±3 days after treatment (Figure 4D). We monitored
hemoglobin and platelet counts in mice to assess leukemic
cell bone marrow involvement. In PBS-treated control mice
inoculated with BPDCN, hemoglobin and platelet counts
progressively decreased until death. In contrast, in treated
mice, these hematologic parameters reached the levels
observed in irradiated control mice that were not inocula ted
Figure 2. Sensitivity of primary BPDCN cells to SL-401 and other rele -
vant chemotherapeutic agents. The mean percentages of viable
cells (AV-/7-AAD- cells) from three patients (# 7, 9 and 11) after treat-
ment with with SL-401 (365 pM), Erwinia L-asparaginase (L-ASP, 10
IU/mL), asparaginase (ASP, 10 IU/mL), methotrexate (MTX, 9.9 mM),
cyclophosphamide (CYC, 100 IU/mL), cytosine arabinoside (CYT,
0.329 mM), dexamethasone (DEX, 0.637 mM), vincristine (VIN,
0.0242 mM) and idarubicin (IDA, 0.158 mM). Untreated cells were
considered as 100% viable. Histograms represent the mean ± SEM
of three independent experiments (*P<0.05 between SL-401 and all
other drugs pairwise except IDA).
Figure 3. Comparison of sensitivity of primary blasts from patients
with BPDCN, acute lymphoid leukemia (ALL), and acute myeloid
leukemia (AML) to SL-401-mediated death. Leukemia blasts sam-
pled from three patients with ALL (2 B-ALL and 1 T-ALL) and six
patients with AML (1 case of AML with multilineage dysplasia, 2
cases of M1 AML, 1 case of M0 AML, and 2 cases of M2 AML) and
blasts from 11 BPDCN patients (#1-10 and 12) were cultured with or
without SL-401 (365 pM) for 18 h. The viability was assessed by flow
cytometry (AV-/7-AAD- cells). The bars represent the mean ± SEM of
the percentage viable blastic cells, with untreated cells considered
100% viable. **P<0.001.
Table 2. Expression of IL-3Ra and β chains on primary malignant cells from
patients suffering from BPDCN, acute myeloid leukemia (AML) cells, acute
lymphoid leukemia (ALL) cells and cell lines −as assessed by mean fluores-
cence intensity − was compared with the viability after treatment with SL-401. 
Cells Mean fluorescence Viability (%) IC50
intensity
IL-3R a (CD123) IL-3R β (CD131) (365 pM) (pM)
#1 6340 2214 29▪ 0.06
#2 10189 2352 38▪ 0.083
#3 9095 2060 17* 0.006
#4 10746 2320 17* NA
#7 6165 3276 27* NA
#9 4439 2477 29* NA
#10 diagnosis 5509 3433 6±1° 0.006
#10 relapse 5137 1068 5±1.3# 0.075
AML 1 4557 2073 83▪ NA
AML 1 2073 1870 93▪ NA
AML MLD 6941 3003 100▪ NA
AML 2 3700 1473 93▪ NA
AML 2 1068 2749 93▪ NA
ALL-T 3049 2761 94▪ NA
ALL-B 2399 2890 87▪ NA
GEN2.2 11336 5378 0,45* 0.006
CAL-1 6406 629 12,5* 0.05
TF/hras 1478 1174 75* 0.06
Expression of IL-3Ra and β chains (CD123 and CD131) −measured by flow cytometry− in
BPDCN cells from patients (# 1-4, 7, 9 and 10), or in different AML, ALL and cell lines (results rep-
resent the mean of 2 determinations). Percentage of viability after culture with SL-401 (experi-
mental dose 365 pM= 21 ng/mL) in one experiment (▪), mean±SEM of two (*), three (°) or six
(#) indepen dent evaluations and IC50 are indicated. AML MLD: AML with multi lineage dysplasia;
NA: not available.
100
80
60
40
20
0
**
100
80
60
40
20
0
Drugs
*
%
 v
ia
bi
lit
y
%
 v
ia
bi
lit
y
AL
L
No
 SL
-40
1
SL
-40
1
L-A
SP AS
P
MT
X
CY
C CY
T
DE
X
VIN ID
A
AL
L+
SL
-40
1
AM
L+
SL
-40
1
BP
DC
N
BP
DC
N+
SL
-40
1
AM
L
IL-3R-targeted treatment of BPDCN
haematologica | 2015; 100(2) 227
with BPDCN cells and not treated (Figure 4E). Regression of
cytopenia under treatment indicates an absence, or at least,
a lower level of bone marrow involvement by BPDCN cells
in SL-401 treated mice. Overall, SL-401 is effective in con-
trolling BPDCN cells in vivo.
Discussion
SL-401 is a biologic agent corresponding to IL-3 geneti-
cally fused to truncated DT via a cleavable linker. This
agent induces cytotoxicity by inhibiting ribosomal func-
tion, and thereby, inhibiting protein synthesis, a mecha-
nism that is distinct from all other anticancer
therapeutics.20 SL-401 has been demonstrated to induce a
profound cytotoxicity at picomolar and subpicomolar
concentrations in AML cell lines,26 as well as in a model of
human AML inoculated into immunocompromised
mice.27 Moreover, SL-401 is cytotoxic in vivo, in patients
with advanced AML and myelosdysplastic syndrome,23
suggesting that SL-401 targets leukemic stem cells, as well
as more mature tumor cells. In contrast, SL-401 is not
cytotoxic to normal hematopoietic progenitor cells,28
which has translated into a paucity of myelosuppression
in clinical trials to date.23,28-31
The present study was performed to evaluate and quan-
tify the effects of SL-401 on various preclinical models of
BPDCN, a malignancy that ubiquitously expresses high
levels of the IL-3Ra chain, which is the target of SL-401.
The results reported here demonstrate that SL-401 is high-
ly potent against BPDCN cell lines and primary BPDCN
blasts obtained from patients. Although AML cell lines
and primary AML cells have demonstrated sensitivity to
SL-401 with IC50 values in the picomolar range (10-12 M),23
which are lower than plasma concentrations achieved in
leukemic patients undergoing treatment with SL-401,
BPDCN blasts are more sensitive, with IC50 values in the
femtomolar range (10-15 M, experimental dose 0 to 21
ng/mL).32 In addition, SL-401 produced a robust antitumor
effect in an in vivo xenograft model using human BPDCN
cells. This also indicates a potential good therapeutic
index, as well as systemic activity, since mice survived
more than 40 days after SL-401 treatment. The high sensi-
tivity of BPDCN to SL-401 and the potential good thera-
peutic index of this agent likely reflect the high specificity
of the IL-3 ligand component of SL-401 for CD123, in
addition to the mechanism of action and potency for its
DT payload. Since the IL-3 component of SL-401 is bound
via an amino acid linker to a DT for which the receptor
binding site is truncated, free DT is essentially inert from
a toxicity standpoint. DT can only be delivered intracellu-
larly following the binding of SL-401 to the IL-3R via IL-3
and internalization. Since IL-3Ra expression is limited to
only a few normal tissues (plasmacytoid dendritic cells
and basophils) and, in contrast, the receptor is over-
expressed by BPDCN cells, SL-401 can potentially confer
high therapeutic indexes for patients. Additionally, SL-401
is not a substrate for p-glycoprotein and other efflux
F. Angelot-Delettre et al.
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Figure 4. In vivo efficacy of SL-401 in a NSG mouse model inoculated with BPDCN cells. NSG mice were irradiated with 2 Gy and then inocu-
lated intravenously with 1x106 GEN2.2 BPDCN cells on day 0. (A) Overall survival (OS) of BPDCN inoculated-mice treated with SL-401 (solid
line; n=4) or with PBS (dotted line; n = 3). Treatment with SL-401 (2 mg/mouse intraperitoneally, experimental dose 100 mg/kg) performed
daily for 5 days, was begun on day 7 (pink bar). OS from one representative experiments out of three is shown (P=0.3). (B) Mean OS of BPDCN
inoculated-mice treated with SL-401 (n=8) or PBS (n=8) from three independent experiments (**P<0.001). (C) one example of the immuno -
staining of circulating peripheral blood mononuclear cells performed at day 53 prior to sacrifice. Murine (blue) and human GEN 2.2 (red) cells
are distinguishable due to specific CD45 antibody expression. Human GEN2.2 BPDCN cells express CD123, BDCA4, CD4, CD56, but not CD34
or CD3. (D) BPDCN cell count values in the blood of a mouse following treatment with SL-401 (dotted line, black circles) or with PBS (blue
solid line, blue square). (E) Means of hemoglobin, as well as white blood cell and platelet counts in the blood of mice following treatment with
SL-401 (n=4) or saline control (n=3). The gray line represents blood parameter values in irradiated mice that were not treated with SL-401. †:
means that the mice died.
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pumps, and thus, cannot be excluded from the blastic
cells. Moreover, its cytotoxic mechanism, binding to ADP-
ribosylated elongation factor 2, thereby uncoupling pro-
tein synthesis blockade, does not overlap with other
agents currently used.22 IL-3 has also been shown to be a
critical survival factor for plasmacytoid dendritic cells.33
Thus, interference of this pathway by SL-401 may explain
the high sensitivity of BPDCN compared with the sensi-
tivity of other myeloid and lymphoid leukemic cells.
There is still no consensus on the best therapeutic
approach for BPDCN,3,12-15,34-38 and, overall, BPDCN
remains a chemotherapy-resistant disease and may also
resist the graft-versus-leukemia effect, since 32% of
patients relapse after allogeneic hematopoietic cell trans-
plantation according to a recent study.13 Thus, targeted or
immune-based therapies are alternative strategies to treat
this aggressive leukemia.39-41 Here, we propose that SL-401
is an efficient target-based therapy available for clinical tri-
als and has already been shown to have favorable effects
in patients with refractory or relapsed AML or myelodys-
plastic syndrome, although expression of CD123 is lower
on myeloid blasts than on BPDCN cells.23 We recently
published data from a phase I/II clinical study involving 11
BPDCN patients. These data showed that a single cycle of
SL-401 induced major responses in 78% of the patients.24
The way to use SL-401 in BPDCN patients must, howe ver,
be discussed in the light of data from literature obtained in
such patients. SL-401 can be used to consolidate the
effects of first-line chemotherapy, reducing the number of
relapses, which always occur after chemothe rapy treat-
ment. The combination of SL-401 with chemotherapy
should make it possible to reduce chemotherapy doses,
and consequently, their adverse effects, which are signifi-
cant in elderly patients with comorbidities (i.e., most of
the patients with BPDCN). We showed here that idaru-
bicin, at the dose we tested, induces a relevant level of
cytotoxic activity in vitro whereas cytosine arabinoside
does not. This confirms recent data showing that the
BPDCN cell line CAL-1 is resistant to cytosine arabi-
noside.41 Intrathecal injection of SL-401 could also be of
interest since there are frequently patients with central
nervous system relapse42 and the molecular weight of SL-
401 (57 KDa) predicts no diffusion across the blood-brain
barrier. For patients who undergo allogeneic hematopoiet-
ic cell transplantation, SL-401 treatment can be used
before allografting to minimize the level of minimal resid-
ual disease, which is the most important prognostic factor
in a recent study on allografted BPDCN patients,13 or as a
consolidation treatment after allogeneic hematopoietic
cell transplantation.13 In support of this latter use, we
observed that, in vitro, the blastic cells from a relapsing
BPDCN patient were still sensitive to SL-401-mediated
death. Moreover, the IL-3Ra chain (CD123) was still
expressed on the surface at relapse (CD123 MFI at diagno-
sis: 5509 versus 5137 at relapse, patient #10). In the mouse
model after one course of SL-401, all the BPDCN cells at
relapse also expressed CD123. This supports the hypoth-
esis that patients suffering from BPDCN can be treated
with SL-401 as first-line or second-line therapy and,
maybe, even with several courses of SL-401. Overall,
immune-based therapy using SL-401 appears to be an
appropriate way to treat BPDCN patients. New approach-
es based on immunomodulators41 or demethylating
agents40 must be further evaluated and compared − or
associated − with SL-401.
In conclusion, we demonstrate that clinical grade SL-
401, which specifically targets IL-3R, efficiently kills pri-
mary BPDCN cells in culture and significantly improves
the overall survival of mice inoculated with BPDCN
receiving a single cycle of SL-401. This provides a strong
rationale for the use of SL-401 in the treatment of patients
suffering from BPDCN. As BPDCN is a rare subtype of
leukemia, an international clinical trial using SL-401
should now be conducted to validate these results
prospectively.
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